Lilly Broadens Its CNS Reach With Rigel RIPK1 Deal
Joins Sanofi And Denali In Class
The RIPK1 inhibitor class has yet to reach proof-of-concept, but could bolster Lilly’s dogged pursuit of progress in Alzheimer’s disease.
The RIPK1 inhibitor class has yet to reach proof-of-concept, but could bolster Lilly’s dogged pursuit of progress in Alzheimer’s disease.